凯普西塔诱导的冠状动脉,导致多形心室性心动减速和心脏骤停
Maciej Kabat1, Roma Padalkar2, Sara Hazaveh2
1Department of Internal Medicine, Hackensack University Medical Center, 30 Prospect Avenue, Hackensack, NJ, 07601, USA. maciej.kabat@hmhn.org.
Cardio-oncology (London, England)
|February 28, 2024
概括
一种癌症药物卡佩奇他可以导致冠状动脉,一种严重的心脏并发症. 早期识别和管理,包括以患者为中心的决策,对于安全治疗至关重要.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 卡佩奇他是一种广泛用于治疗乳腺癌和结肠直肠癌的化疗剂.
- 常见的副作用已得到充分证实,但冠状动脉血管等心脏并发症不太知名.
- 基于烯胺的疗法可以通过各种拟议的机制触发血管的事件.
研究的目的:
- 报告一个capecitabine诱导的冠心血管的病例.
- 突出这种罕见的不良影响的诊断和管理挑战.
- 强调以患者为中心的护理在管理严重治疗并发症中的重要性.
主要方法:
- 一个患有sigmoid结肠癌的患者用capecitabine治疗的病例报告.
- 使用遥测对心脏事件的监测.
- 开始治疗通道阻塞剂,并讨论植入式心脏转换器-除器的放置.
- 在重新开始用预防药物治疗capecitabine后的随访.
主要成果:
- 患者经历了capecitabine诱导的冠状动脉,导致ST升高,心肌缺血症和多形心室性心跳动.
- 患者之前没有患有心血管疾病.
- 用维拉帕米尔和植入式心脏转换器-除器的治疗是有效的,允许在没有复发的心脏事件的情况下继续治疗capecitabine.
结论:
- 冠状动脉是一个显著的,尽管不常见的,皮他治疗的并发症.
- 迅速识别和适当的心血管管理是必不可少的.
- 在管理意外严重不良事件时,将患者的价值观纳入治疗决策至关重要.
更多相关视频
06:57Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
Published on: January 31, 2019
14.7K
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
9.3K
相关概念视频
01:28Disturbances in Heart Rhythm
952
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
952
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
01:28Mechanism of Cardiac Arrhythmias
919
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
919
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
743
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
743
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
994
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
994
01:30Cardiac Action Potential
1.4K
Cardiac action potentials are essential for proper heart function, enabling the rhythmic contractions needed for adequate blood circulation. Nodal cells and Purkinje fibers, specialized for electrical conduction, generate these action potentials.
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
1.4K